View in Other Languages

Pfizer Inc.

NYSE:PFE ISIN:US7170811035

Pfizer Inc.(NASDAQ: PFE). The Group's principal activities are to discover, develop, manufacture and market prescription medicines for humans and animals as well as many of the world's best-known consumer products. The Group operates in two business segments pharmaceuticals and consumer products. Pharmaceuticals segment includes prescription pharmaceuticals for treating cardiovascular diseases, infectious diseases, central nervous system disorders, diabetes, erectile dysfunction, allergies, arthritis and other disorders. The major revenue generating pharmaceutical products are Lipitor, Norvasc, Cardura, Accupril, Zithromax, Viracept, Zoloft, Neurontin, Viagra and Zyrtec. Consumer products segment includes consumer health care products, confectionery products, shaving products and tetra fish products. Pharmaceutical products accounted for 84% of 2001 revenues and consumer products, 16%.



Asian Activities Report for December 7, 2011: Great Wall Motors (HKG:2333) Receives EU Whole Vehicle Type Approval for Voleex C30 and Voleex C20R

🕔12/7/2011 11:27:21 AM 8602

Asian Activities Report for December 7, 2011 includes: Great Wall Motors (HKG:2333) has received EU Whole Vehicle Type Approval for its Voleex C30 and Voleex C20R; Chevalier International Holdings Limited (HKG:0025) has entered into a letter of intent in relation to possible acquisitions of certain hot spring hotels in Japan; Daiichi Sankyo Co., Ltd (TYO:4568) advises that its subsidiary Ranbaxy Laboratories Ltd. (BOM:500359), India's largest pharmaceutical company, has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin, a cholesterol-reducing medicine, in the US market.

Read Full Article

Benitec Limited (ASX:BLT) Receives Dividend from Licensee

🕔12/23/2010 4:18:26 PM 6561

Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to advise that it will receive a dividend of US$161,674 from its licensee, the California-based biotechnology company, Tacere Therapeutics, Inc.

Read Full Article

Australian Market Report of December 20, 2010: IMX Resources (ASX:IXR) Sailed First Shipment of Iron-Copper Ore to China

🕔12/20/2010 1:30:00 PM 10725

Australian Market Report of December 20, 2010 includes: IMX Resources Limited (ASX:IXR) has sailed its first shipment of iron-copper ore to China; Phylogica Limited (ASX:PYC) signed collaboration and licensing deal with Pfizer (NYSE:PFE); Copper Strike Limited (ASX:CSE) received strong copper/silver/cobalt results at Walford Creek in Northwest Queensland; South American Ferro Metals Limited (ASX:SFZ) iron ore production in Brazil exceeds 400,000 tonnes.

Read Full Article

Benitec Limited (ASX:BLT) Granted Further Hepatitis C RNAi Patent In US

🕔9/29/2010 11:02:23 AM 4979

Benitec Limited (ASX:BLT) (PINK:BNIKF), a leading Australian based company specialising in RNA interference (RNAi) technology, is pleased to announce that the US patent application for "RNAi Expression Constructs" has been successfully granted by the United States Patent and Trademark Office (USPTO) as US Patent No. 7,803,611.

Read Full Article

Benitec Limited (ASX:BLT) Half Yearly Accounts

🕔2/26/2010 3:19:00 PM 7648

Benitec Limited (ASX:BLT) (PINK:BNIKF) is one of the pioneers of RNA interference (RNAi) technology, which can be used to precisely destroy RNA viruses and silence the expression of defective genes. Benitec's core patents and licenses provide key technologies to trigger RNAi in human cells and in live animals. Benitec holds exclusive worldwide rights for the development and commercialisation of all therapeutic human applications.

Read Full Article

ABN Newswire Stocks to Watch: February 8, 2010

🕔2/8/2010 11:30:47 AM 16044

ABN Newswire stocks to watch today include: Emergent Resources Limited (ASX:EMG), Benitec Limited (ASX:BLT)(PINK:BNIKF), Legend Mining Limited (ASX:LEG) (PINK:LGDMF) and Drillsearch Energy Limited (ASX:DLS) (PINK:DRLLF).

Read Full Article

Benitec Limited (ASX:BLT) Licensee Achieves Significant Milestone With Pfizer (NYSE:PFE)

🕔2/5/2010 10:38:19 AM 8666

Benitec Limited (ASX:BLT)(PINK:BNIKF) licensee company Tacere Therapeutics, Inc. announced today that Pfizer (NYSE:PFE) has exercised the option, granted in a collaboration and license agreement previously announced in January 2008, to further develop and commercialise Tacere's Hepatitis C Virus (HCV) compounds.

Read Full Article


  • This Page Viewed: (Last 7 Days: 17) (Last 30 Days: 54) (Since Published: 15227) 

Company Data

    ChairmanDr. Henry A. McKinnell  Principal Sector
  • Health & Pharm General 
  • Principal Industry
  • Healthcare 
  • Homepage

Social Media